Trial Profile

A phase III Equivalence Trial of PF 582 for the Treatment of Macular Degeneration (AMD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Wet age-related macular degeneration
Focus Registrational; Therapeutic Use

Most Recent Events

09 May 2016 According to a Pfenex media release, the company is planning to initiate this trial in the second half of 2016.
16 Mar 2015 According to Pfenex media release, company is planning to initiate this trial in 2016.
12 Feb 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com